Physician profile
Howard Fein
NPI 1184707838
$18,893.89
in general payments reported to CMS, 2019-2025
30 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 79% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $277 · 2021: $409 · 2022: $7,327 · 2023: $7,130 · 2024: $1,944 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,573 · Food and Beverage: $3,173 · Travel and Lodging: $496 · Grant: $60.00 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,572.50 |
| Food and Beverage | $3,172.98 |
| Travel and Lodging | $496.32 |
| Grant | $60.00 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $13,883.47 | 2022-2025 | Opzelura |
| Genzyme Corporation | $973.08 | 2019-2025 | |
| Abbvie INC. | $758.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $433.44 | 2022-2025 | Dupixent |
| Pfizer INC. | $372.10 | 2019-2025 | |
| Mimedx Group, INC. | $350.41 | 2024-2025 | |
| Ucb, INC. | $336.69 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $265.53 | 2019-2025 | |
| Janssen Biotech, INC. | $258.40 | 2019-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $199.00 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $172.85 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $142.14 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123.61 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Mayne Pharma Commercial LLC | $119.87 | 2019-2020 | |
| Amgen INC. | $85.93 | 2024 | Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $79.00 | 2021-2024 | Seysara |
| Leo Pharma INC. | $77.86 | 2021-2022 | |
| Dermira, INC. | $38.66 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $33.01 | 2023 | Ycanth |
| Medimetriks Pharmaceuticals, INC. | $31.24 | 2019-2023 | Neo-Synalar |
| E.R. Squibb & Sons, L.L.C. | $23.34 | 2024 | Sotyktu |
| Organon LLC | $21.47 | 2025 | Vtama |
| Journey Medical Corporation | $20.30 | 2022 | |
| Dusa Pharmaceuticals, INC. | $19.43 | 2019 | |
| Sebela Pharmaceuticals INC. | $18.20 | 2022 | |
| Strata Skin Sciences, INC. | $18.15 | 2025 | Xtrac |
| Bsn Medical INC | $15.41 | 2022 | |
| Allergan, INC. | $11.60 | 2019 | |
| Sandoz INC. | $11.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Fein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.